Meyers 2009.

Study characteristics
Methods	Randomised double‐blind study
Participants	259 participants; DSM‐IV‐TR psychotic depression; 18 years of age or older; HAM‐D ≧ 21 and SADS delusional severity rating ≧ 3 Inpatients
Interventions	12 weeks' treatment with olanzapine + placebo and olanzapine + sertraline
Outcomes	Remission rates (HAM‐D 17 ≦ 10 and SADS delusional item score = 1)
Notes	53% dropout in olanzapine arm and 37% dropout in olanzapine + sertraline arm
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	As reported: "computer generated randomisation list"
Allocation concealment (selection bias)	Unclear risk	No further data
Blinding (performance bias and detection bias) of participants	Low risk	Study was double‐blind (reported as: "sertraline and placebo under double‐blind conditions")
Blinding (performance bias and detection bias) of personnel	Low risk	Well‐described double‐blinding. "Sertraline and placebo under double‐blind conditions". As reported: "investigators and raters were blind to treatment assignment"
Blinding (performance bias and detection bias) of outcome assessors	Low risk	Well‐described double‐blinding. "Sertraline and placebo under double‐blind conditions". As reported: "investigators and raters were blind to treatment assignment"
Incomplete outcome data (attrition bias) All outcomes	Low risk	None
Selective reporting (reporting bias)	Low risk	Protocol available. Generally accepted outcomes have been used
Other bias	Unclear risk	Relatively high dropout rate with significant differences between treatment groups (53% olanzapine and 37% olanzapine + sertraline) Patients with only hallucinations excluded